France Reduces Opiate Overdose Death Rate by 79%: U.S. Should Follow Suit

In the 1980s, France went through a heroin epidemic in which hundreds of thousands became addicted. The rate of overdose deaths was rising 10 percent a year, yet treatment was mostly limited to counseling at special substance-abuse clinics. In 1995, France made it so any doctor could prescribe buprenorphine without any special licensing or training. Buprenorphine, a first-line treatment for opioid addiction, is a medication that reduces cravings for opioids without becoming addictive itself.

With the change in policy, the majority of buprenorphine prescribers in France became primary-care doctors, rather than addiction specialists or psychiatrists. Suddenly, about 10 times as many addicted patients began receiving medication-assisted treatment, and half the country’s heroin users were being treated. Within four years, overdose deaths had declined by 79 percent.

France has a socialized medical system so many users don’t have to worry about cost, and the country also developed a syringe-exchange program around the same time. Some of the users did sell or inject the buprenorphine (as opposed to taking it orally, as indicated), though these practices didn’t result in nearly as many deaths as heroin does.

“It seems that the French model raises questions about the value of tight regulations imposed by many countries throughout the world,” wrote the author of a study on the phenomenon, the French psychiatrist Marc Auriacombe, in 2004. Just what are these regulations? In the United States, doctors must take a special, eight-hour class to get a waiver that allows them to prescribe buprenorphine. The classes can cost money and force even more tasks into doctors’ already packed schedules. In one study, 10 percent of doctors said they didn’t even know how to get the waiver.

According to Andrew Kolodny, a psychiatrist who studies addiction at Brandeis University, some primary-care doctors might frankly be daunted by the prospect of working with addicted patients—a sentiment that’s also reflected in physician surveys. Meanwhile, there is no special training class required to prescribe prescription painkillers, Kolodny points out. (There’s also a cap on how many buprenorphine patients a single doctor can have, though Congress is considering waiving this limit through new legislation.)

There are multiple other issues in the American health-care system that make accessing buprenorphine difficult for addicted people. Medicaid pays for a substantial chunk of all drug-abuse treatment, but state Medicaid programs impose limits on when and how they’ll cover buprenorphine. Doctors know that if they sign up to prescribe buprenorphine, all the local heroin users will flock to them, potentially crowding out their other patients, says Stanford University professor of psychiatry Keith Humphreys. “If you really want someone who’s addicted to seek treatment, you have to have it be less expensive than using heroin,” Kolodny said. For many addicted Americans, that’s not currently the case.

Sign In or Register to comment.